The best therapy regimen for refractory obstetrical antiphospholipid syndrome remains to be determined. Additional treatments with steroids, plasma exchanges and immunoglobulins failed to show any beneficial effect. We present a case of a woman who had a better pregnancy outcome after the administration of hydroxychloroquine (HCQ) as additional treatment. Furthermore, we highlighted that HCQ was able to dramatically reduce the antiphospholipid antibodies levels.
Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment? / De Carolis, S; Botta, A.; Salvi, S.; di Pasquo, E.; Del Sordo, G.; Garufi, Cristina; Lanzone, A.; De Carolis, M. P.. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - ELETTRONICO. - 14:9(2015), pp. 760-762. [10.1016/j.autrev.2015.04.010]
Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?
GARUFI, CRISTINA;
2015
Abstract
The best therapy regimen for refractory obstetrical antiphospholipid syndrome remains to be determined. Additional treatments with steroids, plasma exchanges and immunoglobulins failed to show any beneficial effect. We present a case of a woman who had a better pregnancy outcome after the administration of hydroxychloroquine (HCQ) as additional treatment. Furthermore, we highlighted that HCQ was able to dramatically reduce the antiphospholipid antibodies levels.| File | Dimensione | Formato | |
|---|---|---|---|
|
DeCarolis_hydroxychloroquine_2015.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
224.69 kB
Formato
Adobe PDF
|
224.69 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
